Indian drugmakers in a modern pharmaceutical facility, with growth charts overlaid.
Competition is intensifying in India’s obesity drug market as multiple domestic drugmakers launch generic versions of popular weight-loss medications following patent expiry. This aims to increase accessibility in a price-sensitive nation, with experts anticipating significant market growth by 2030.
The price of some weight-loss drugs has dropped dramatically, from Rs 450 to Rs 4,200, as Indian companies rush to capture market share. The entry of generic alternatives is expected to make these treatments more affordable, potentially reaching a broader segment of the population.
However, the reduced prices also raise concerns about potential misuse and confusion among doctors. Experts emphasize the need for careful monitoring and regulation to ensure responsible use of these medications.
The obesity drug market in India is poised for substantial expansion, driven by increased awareness and the availability of cheaper alternatives. The entry of multiple players is indicative of the perceived growth potential in this sector, attracting significant investment and strategic maneuvering.
About the Author
